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ABSTRACT
Voltage-gated sodium channel (Nav) expression in non-excitable cells has raised questions regard-
ing their non-canonical roles. Interestingly, a growing body of evidence also points towards the
prevalence of aberrant Nav expression in malignant tumors, potentially opening a new therapeu-
tic window. In this study, the transcriptional consequences of channel inhibition were investigated
in non-small cell lung carcinoma H460 and neuroblastoma SH-SYSY cell lines, that both express
Nav1.7. Channel activity was blocked by the application of both selective, ProTx-II, and non-
selective, tetrodotoxin, inhibitors. Global gene expression profiling did not point to any statisti-
cally significant inhibition-associated perturbation of the transcriptome. A small subset of genes
that showed relatively consistent changes across multiple treatments were further assayed in the
context of a multiplex bead expression array which failed to recapitulate the changes seen in the
global array. We conclude that there is no robust transcriptional signature associated with the
inhibition of two sodium channel expressing cancer cell lines and consequently sodium channel
inhibition will not lend itself to therapeutic approaches such as transcription-based drug
repurposing.
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Introduction
Voltage-gated sodium (Nav) channels were ori-
ginally characterized as prominent players in
signal conduction in excitable cells, such as neu-
rons and myocytes, principally through the reg-
ulation of cellular ion balance [1,2]. Subsequent
findings led to speculation that Nav channels
may also be involved in a wider repertoire of
cellular processes [3]. One notable observation
was that Nav channels are not exclusively pre-
sent in excitable cells and appear to take on roles
that are not necessarily related to action poten-
tial generation and cellular excitability [4]. For
example, functional expression of the channels
has been observed in cancer cells, with record-
ings of voltage-gated sodium currents in human
leukemia [5] and small-cell lung cancer cells [6].
Over the years, innumerable studies from inde-
pendent research groups have added to a rapidly
expanding body of evidence for the functional
expression of Nav channels in non-excitable cells
of wide-ranging backgrounds including, red
blood cells [7], macrophages [8], oligodendro-
cytes [9], dendritic cells [10], and fibroblasts
[11]. The expression of Nav channels in these
cells is dynamic, and may alter depending on the
developmental, physiological, and pathological
state [12,13]. This dynamic expression profile
has been linked to distinct biological states of
the cell serving to implement diverse biological
functions, e.g. motility, endosomal acidification,
and phagocytosis [14,15].
The functional relevance of Nav channels in
a non-excitable context has been most intensely
investigated in cancerous cells. This focus could
certainly be explained in part by the fact that Nav
channels are anomalously expressed in a wide
range of tumors, including, lymphoma, breast can-
cer, melanoma, colon, and ovarian cancer [16]. In
some cases, the channels are not present in the
corresponding healthy tissues, e.g., breast cancer
[17]. On the other hand, in certain cancers, such as
glioma and ovarian cancer, Nav channels are
expressed in the healthy counterparts [18,19]. In
the latter case, the degree of channel overexpres-
sion is tied to the aggressiveness of cancer metas-
tasis [20]. The mechanisms by which Nav channels
exert their metastasis-related effects are only
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beginning to be unraveled and thus far results have
largely been obtained from breast and prostate
cancer studies [21]. Sodium ions are clearly an
important factor, still how much of the observed
response is due to the fluctuation in Na+ concen-
tration, membrane potential, or transporter-
assisted ion exchange, has yet to be fully charac-
terized [22]. One school of thought believes the
interaction between Nav channels and partner pro-
teins to be critical, based on accumulating evi-
dence that various scaffolding proteins partner
with the channels to form multiprotein complexes
[23,24].
Nav channels exist in several isoforms which are
distributed in distinct cell types and locations, e.g.,
Nav1.1 is expressed in both the CNS and PNS to
Nav1.9 predominantly in the PNS [25]. Mutations in
Nav1.7 are associated with painful channelopathies
and congenital insensitivity to pain [26,27]; it comes
as no surprise that this channel has been a prime
target for pain management [28]. Interestingly, paral-
lel work has revealed Nav1.7 upregulation in
a number of tumors, for example, breast [17], prostate
[29], gastric [30], and non-small cell lung cancer [31].
This overexpression is reportedly associated with
tumor-related transcriptional changes and is linked
to the aggressive phenotypes exhibited by the meta-
static cells [14,30,32]. It follows that suppression of
Nav1.7 expression or activity might improve cancer
prognosis. In fact, there is speculation that the use of
analgesics that engageNav channels for cancer surgery
may have implications in lessening tumor reoccur-
rence [33].
In the present work, we have sought to elucidate
the functional consequence of sodium channel
expression in the cancer context by following
changes in gene expression upon channel inhibi-
tion. The possibility that there are transcriptional
changes associated with channel inhibition could
potentially open up new avenue for therapeutic
screening and possible drug repurposing [34–38]
based on the wealth of available drug-associated
transcriptional data [39]. Nav1.7 has been shown
to be the prominent Nav subtype in the H460 lung
cancer and SH-SY5Y neuroblastoma cell lines
[31,40] and we decided to investigate channel
activity in these two cell lines with a specific Nav
1.7 antagonist and a more general inhibitor.
Specifically, the pufferfish derived neurotoxin
tetrodotoxin (TTX) has been shown to block
a subset of Nav channels (TTX sensitive Nav
1.1–1.4 and Nav1.6–1.7; Pinto, Derkach [41]),
and the tarantula derived neurotoxin ProTx-II
exhibits Nav1.7 selectivity [42].
Methods
Pharmacological treatment and microarray
SH-SY5Y neuroblastoma cell line was kindly
provided by Dr Paul Francis’ group (Wolfson
CARD, KCL UK), and maintained in DMEM-
high glucose medium at 37°C, 5% CO2. NCI-
H460 non-small cell lung cancer cell line was
purchased from ATCC USA and maintained in
RPMI 1640-GlutaMAX medium at 37°C, 5%
CO2. Cells were passaged 2–3 times a week.
Complete growth media for both cell lines were
supplemented with 10% FBS (PAA Laboratories,
UK), 100 U/mL penicillin, and 100 μg/mL strep-
tomycin. All culture media and supplements
were purchased from Sigma-Aldrich, UK, unless
otherwise stated.
For the experiments, SH-SY5Y and H460 cells
were seeded at 100,000 cells per well in a 12-well
sterile cell culture plate and incubated for 48 h to
reach approximately 80% confluence. Cells were
then treated for 6 h with 1 μM TTX (Sigma-
Aldrich), 1 or 10 nM ProTx-II (SmarTox); as the
IC50 of ProTx-II for Nav1.7 is approximately 1 nM
[43], we decided to work with concentrations in
the range 1 to 10 nM. Each treatment was repli-
cated in four culture wells. Following this, culture
media were removed, and the cells were lysed in
Absolutely RNA Miniprep Kit lysis buffer and β-
mercaptoethanol (Agilent Technologies, UK).
RNA was then extracted, and quality assessed
(RNA Integrity Number ≥8). RNA expression
levels were measured on Affymetrix Human
Genome U133 plus 2.0 (GPL570) chip following
the supplier’s recommended procedure. Resulting
expression data were pre-processed with
Affymetrix MAS5.0.
Multiplex assay
A custom-made set of paramagnetic microbeads
comprising detection probes for 50 genes (44
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chosen based on preliminary analysis and 6
housekeepers) was supplied by Luminex
(Thermo Fisher Scientific). Assay components
were stored at 2–8 ⁰C or −20 ⁰C according to
storage specification.
For one well on a 96-well plate, working bead
solution was made up by mixing 9.2 µL nuclease-
free water, 6.6 µL lysis buffer, 1 µL blocking
reagent, 0.2 µL proteinase K, 0.5 µL capture
beads, and 2.5 µL probe set, totaling 20 µL. All
reagents were supplied as part of the Plex Assay
Kit (QuantiGene, UK). Eighty microliters of cell
lysate and 20 µL working bead solution were
mixed and added to each well. Three blanks and
a positive control were included in every run. The
assay plate was incubated for 18 h at 54⁰C,
600 rpm. After overnight hybridization, the plate
was secured on a magnetic hand-held platform,
and the assay wells were rinsed 3X with 100 µ
wash buffer. One hundred microliters of pre-
amplifier solution was added and incubated for 1
h at 50⁰C, 600 rpm. The incubation-wash step was
repeated with an amplifier, and label probe solu-
tion. After 3X washes for label probe solution, 100
µL SAPE working reagent (3 µL SAPE per 1 mL
SAPE diluent) was added to each assay well and
incubated for 30 min at RT, 600 rpm. The wells
were washed 3X with SAPE wash buffer. Lastly,
130 µL of SAPE wash buffer was added and mixed
well by agitating at 800 rpm for 3 min. The plate
was read immediately on the MAGPIX platform
with xPONENT software (Luminex, USA).
Validation of cell type
The NCBI GEO hosts 145,000 samples on this
platform, making it the most popular array chip.
The relative expression levels of probes were col-
lected for the GEO data and the given cell types.
The ranks were scaled to lie between zero for the
highest expression probe to unity for the lowest.
The relative rank of each probe was defined as r0rr0
for r< r0and
r0r
1r0 for r > r0, where r and r0 are the
average probe ranks over the given cell type sam-
ples and the set of samples deposited on GEO,
respectively. Probes were then mapped to genes
and in the case of degeneracy, the probe with the
largest relative rank mapping to the gene. The
gene rank profile was taken to be related to the
relative gene expression characterizing the cell
type.
Microarray transcription profiles
Transcription profiles for sodium channel inhibi-
tion were based on within plate treatment versus
control gene expression levels, where the scaled
fold was defined as 2 htihcihtiþhci , were hti and hci are
the average treatment and control levels, respec-
tively. In the case of the cell type profiles, the
averages were taken over the two cell types. Only
folds over 20% passing a t-test threshold of 0.05
were considered. Heat maps for individual gene
and sample pairs were generated based on the gene
expression level relative to the distribution over all
samples, xhxiσx , where x is the expression level, the
brackets indicate the average and the denominator
is the standard deviation.
Bead array transcription profiles
Themedian level fluorescence of between 50 and 100
bead reads was taken to be the measure of the corre-
sponding gene’s RNA level. Gene expression levels in
each well were normalized against the geometric
mean of the total gene set. The normalization
scheme was chosen to maximize the correlation of
the cell type expression profile with that seen in the
microarray data. Expression profiles were defined as
for the microarray analysis, see above.
Results
Cell-specific nature of the microarray profiles
As a first step in establishing the phenotype of the
model cell system, their transcriptional profile was
queried against a database of publicly deposited
gene expression profiles via SPIED [44,45], see
Methods. The top 1000 genes in the H460 and
SH-SY5Y or SHSY rank profiles are overwhel-
mingly up-regulated consisting of (977 up-
regulated and 23 down-regulated) for H460 and
(950 up-regulated and 50 down-regulated) for
SHSY. These profiles served as queries in the
SPIED search. It is perhaps worth pointing out
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here that the level of gene expression unique to
a given cell type will tend to be elevated relative to
a background consisting of a variety of tissue
types. An analogy would be in the context of
division of labor one is characterized by what
one does not by what one does not do. The top
SPIED hits show a high correlation with appro-
priate cell types, validating the cell lineages, with
the H460 query resulting in exclusively H460 pro-
files, Figure 1(a). The neuroblastoma query results
are less exclusively that of the same cell type, but
nonetheless picking out 12 profiles of related cell
phenotype in the top 51, Figure 1(b).
Expression level of sodium channel types
across cell types is shown in Figure 1(c). The
lung cancer cells H460 only express SCN3A and
SCN9A, whereas the neuroblastoma cells SHSY
express SCN1A, SCN2A, SCN3A, and SCN9A.
Gene expression is not affected by channel
inhibition
To investigate whether the modulation of channel
activity has a transcriptional consequence, the extent
of gene expression change was determined with
samples segregated according to treatment type and
compared to a random assignment of sample to
treatment type. The extent to which expression is
driven by the given treatment is then measurable by
a Monte Carlo simulation, counting the number of
times a random assignment has a larger perturbed
gene set [46]. As can be seen from Figure 2(a,b),
neither of the sodium channel inhibitors TTX or
PTX pass a statistical threshold of treatment depen-
dent gene perturbation. Individual profiles generated
from samples from the various plate series were also
compared for consistency in regulation. As can be
seen from Figure 2(c) there appears to be little in the
way of robustness in the conservation of regulated
gene sets, with the numbers going in the same direc-
tion alternately surpassing and coming short of those
going in opposite directions. It can be concluded that
there is no robuts transcriptional signature asso-
ciated with sodium channel inhibition of the the
two cancer cell types, with the caveat that the tran-
scriptional effects would be more pronounced with
higher inhibitor concentrations. However, as with all
pharmacological studies, one must be wary of non-
Figure 1. The relative rank expression profile for the H460 (a) and SHSY (b) samples were queried against human samples in SPIED.
The top hits are listed in the table, showing that they are enriched by samples from corresponding cell types. The correlation is more
pronounced for the H460 cells as these are the subject of more available studies. The SHSY correlations pick out SHSY samples as
well as samples from various brain cancer cells. The two cell lines express the sodium channels SCN3A and SCN9A (c). The
neuroblastoma cells also express SCN1A and SCN2A.
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specificity emerging here, see Park, Carlin [43] and
Pinto, Derkach [41]
Sodium channel gene set
The overall gene expression profiles point to
there being little or no effect of channel mod-
ulation in either cell type examined.
Nonetheless, there may be a restricted gene
set that is consistently perturbed by channel
modulation. To this end, the separate profiles
defined according to cell type, treatment type,
and concentration were generated and com-
pared, see Figure 3(a). There is a small popula-
tion of genes that are consistently perturbed
across treatments and it was reasoned that
these could facilitate a biomarker for channel
modulation. As a positive control for subse-
quent verification, a gene set was designed
based on delimiting the two cell types, see
Figure 3(b).
Bead assay
Comparison of cell type-specific expression is
in good agreement with the array data, Figure
4 explaining this. The bead assay expression
data are given in Figure 5. It is clear that
there is no correlation between predicted
expression direction change and that observed
across 15 independent sodium channel inhibi-
tion treatments.
Conclusions
This study sought to investigate the activity of
sodium channels in the context of cancer cells
through transcriptional profiling. We first
Figure 2. There is no significant transcriptional response upon inhibiting sodium channels in either the lung cancer or neuroblas-
toma cell lines. Monte Carlo significance test of association of gene expression with treatment type shows that neither the SHSY
response (a) or H460 response (b) is significantly elevated beyond a random association of treatment and control groups. The
inhibitor expression profiles generated from independent plate replicates show little consistency, see (c). The entries are colored
according to the sign of the correlation, green for positive and orange for negative.
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Figure 3. The gene sets for validation. The gene set based on consistently regulated genes by the PTX and TTX inhibitors are shown
in (a), the cells are colored according to the scaled fold value, see Methods. Cell type is strongly encoded in relative gene expression
(b) and can serve as a positive control for the multiplex array experiments. The cells are colored according to the Z-score of the
response relative to the average and standard deviation over the full sample set, xhxiσx , where x is the expression level, the brackets
indicate the average and the denominator is the standard deviation.
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showed that the H460 and SH-SY5Y cell pheno-
type could be effectively defined through relative
gene expression and further showed that
a subset of sodium channels is expressed in the
two cell types. Having established sodium chan-
nel expression, we then determined whether
pharmacological intervention would elicit
a transcriptional response by applying inhibitor
toxins that block Nav channels either non-
selectively (TTX) or with Nav1.7 specificity
(ProTx-II). Our initial microarray results sug-
gested that these inhibitors do not induce con-
sistent alterations in overall gene expression in
either of the two cell lines as indicated by Monte
Carlo significance test and inter-profile compar-
ison. Nonetheless, we reasoned that there might
still be a restricted gene set that responds to
channel modulation and selected a subset of
genes from the microarray data for further vali-
dation in a multiplex platform. Two distinct
multiplex biomarker gene sets were defined to,
first of all, validate the platform through cell-
specific marker expression and subsequently to
test the validity of inhibitor-associated changes
observed in the microarray data. The multiplex
platform successfully delimited the cell type
based on the expression of cell type marker
genes but failed to reproduce the putative inhi-
bitor-associated changes. We, therefore, con-
clude that in the context of gene expression
there is no robust sodium channel activity in
the two cancer cell lines under normal culture
conditions. Consequently, assuming channel
inhibition is a potential therapeutic target in
cancer our results indicate that transcription-
based approaches are unlikely to succeed.
However, there is a possibility that the sodium
channel activity is transcriptionally silent or that
expression changes are not substantial enough
for the two independent platforms to detect.
For example, by altering membrane potential
the channels might cause localized calcium
influx and kinase activation in a manner that
might impact on migration and/or proliferation
in the absence of substantial transcriptional
changes. Further, it must be borne in mind
that our results are based on cells grown under
normal culture conditions and there remains the
Figure 4. The cell type tracker set effectively segregates the lung cancer and neuroblastoma cells. The cells are colored according to
the Z-score of the response relative to the average and standard deviation over the full sample set, xhxiσx , where x is the expression
level, the brackets indicate the average and the denominator is the standard deviation.
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possibility that the apparently silent channels
might be activated by as yet to be identified
agents and/or conditions.
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